GlassScriptPhysician profile
Toby C Yaltho
NPI 1033399837
$252,292.41
in general payments reported to CMS, 2019-2025
68 companies · $35K in 2025
The $35K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $43K · 2021: $49K · 2022: $41K · 2023: $40K · 2024: $26K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $84K · Food and Beverage: $14K · Consulting Fee: $2,250 · Travel and Lodging: $313 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $84,446.67 |
| Food and Beverage | $13,920.47 |
| Consulting Fee | $2,250.00 |
| Travel and Lodging | $313.39 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $133,696.78 | 2020-2025 | Ubrelvy, Qulipta, Botox |
| Allergan, INC. | $53,207.29 | 2019-2022 | |
| Mdd US Operations, LLC | $23,844.31 | 2019-2025 | Apokyn, Myobloc |
| Acorda Therapeutics, INC | $13,822.45 | 2019-2023 | Ampyra, Inbrija |
| Sunovion Pharmaceuticals INC. | $10,388.95 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $1,424.31 | 2019-2025 | Rytary, Crexont, Ongentys |
| Acadia Pharmaceuticals INC | $1,192.42 | 2020-2025 | Nuplazid |
| Sk Life Science, INC. | $1,166.70 | 2020-2025 | |
| Ucb, INC. | $994.80 | 2021-2025 | Briviact, Rystiggo, Fintepla |
| Novartis Pharmaceuticals Corporation | $981.04 | 2019-2025 | |
| Amgen INC. | $867.17 | 2019-2025 | Uplizna, Aimovig |
| Boston Scientific Corporation | $808.19 | 2019-2024 | Vercise |
| Pfizer INC. | $797.68 | 2022-2025 | |
| Abbott Laboratories | $797.35 | 2019-2025 | Infinity, Proclaim |
| Neurocrine Biosciences, INC. | $775.16 | 2020-2025 | Ingrezza, Ongentys |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $728.34 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Emd Serono, INC. | $670.97 | 2022-2025 | Mavenclad |
| Biogen, INC. | $494.17 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Lilly USA, LLC | $484.92 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Argenx US, INC. | $423.75 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Genentech USA, INC. | $383.04 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Eisai INC. | $309.95 | 2022-2025 | |
| Harmony Biosciences LLC | $305.30 | 2021-2024 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $273.85 | 2022-2025 | Hyqvia |
| Grifols USA, LLC | $262.46 | 2021-2025 | Gamunex-C |
| Genzyme Corporation | $262.39 | 2019-2024 | |
| Lundbeck LLC | $250.05 | 2023-2025 | Vyepti, Rexulti |
| Medtronic, INC. | $248.52 | 2022 | |
| Medtronic USA, INC. | $172.10 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $156.94 | 2021 | |
| Merz Pharmaceuticals, LLC | $150.44 | 2022-2025 | Xeomin, Inbrija |
| Biohaven Pharmaceutical Holding Company LTD. | $144.44 | 2022 | |
| Corium, LLC | $138.86 | 2022-2023 | Adlarity |
| Horizon Therapeutics Plc | $115.64 | 2021-2023 | Uplizna |
| Kyowa Kirin, INC. | $110.31 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $108.10 | 2022-2023 | |
| Arbor Pharmaceuticals, INC. | $93.12 | 2019-2021 | |
| Tanabe Pharma America, INC. | $85.69 | 2024 | |
| Alexion Pharmaceuticals, INC. | $82.25 | 2019-2024 | Ultomiris |
| Neurelis, INC. | $69.50 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $69.19 | 2020 | |
| Jazz Pharmaceuticals INC. | $67.94 | 2022-2024 | |
| Ge Healthcare | $61.17 | 2020-2021 | |
| Almatica Pharma LLC | $59.08 | 2023 | Gralise |
| Azurity Pharmaceuticals, INC. | $55.26 | 2024-2025 | Horizant |
| Avadel Cns Pharmaceuticals, LLC | $54.24 | 2023-2025 | Lumryz |
| Piramal Critical Care | $51.94 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $48.95 | 2022-2023 | Hetlioz |
| Janssen Biotech, INC. | $45.59 | 2025 | |
| Merz North America, INC. | $43.24 | 2019-2020 | |
| Livanova USA, INC. | $38.77 | 2023-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Impel Pharmaceuticals INC. | $37.87 | 2022-2023 | Trudhesa |
| Assertio Therapeutics, INC. | $35.90 | 2019 | |
| Aucta Pharmaceuticals, INC. | $32.96 | 2024 | Motpoly Xr |
| Greenwich Biosciences, INC. | $29.09 | 2019-2021 | |
| Averitas Pharma INC. | $27.99 | 2023 | Qutenza |
| Avion Pharmaceuticals | $26.77 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $26.26 | 2024 | |
| Tg Therapeutics, INC. | $24.72 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $24.53 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.05 | 2022 | |
| Bausch Health US, LLC | $21.81 | 2019 | |
| Vertical Pharmaceuticals, LLC | $20.00 | 2019 | |
| Depuy Synthes Sales INC. | $17.84 | 2021 | |
| Aquestive Therapeutics, INC. | $15.71 | 2022 | |
| Fujirebio Diagnostics, Incorporated | $15.20 | 2019 | |
| Zyla Life Sciences, INC. | $15.06 | 2020 | |
| Insightec,INC | $11.58 | 2024 | Exablate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toby Yaltho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.